Latest H5N1 clinical trials Stories
ROCKVILLE, Md., April 5, 2011 /PRNewswire/ -- Novavax, Inc. (NASDAQ: NVAX) announced that its virus-like particle (VLP) influenza vaccine has been named by the editors of R&D Directions magazine as one of the top "100 great investigational drugs in development" today.
Most parents get their information about vaccines from their children's doctors, but some also consider public health officials, other parents, friends and family members and even celebrities as sources of vaccine information.
Parents also trust family, friends and celebrities, survey finds ANN ARBOR, Mich., April 1, 2011 /PRNewswire-USNewswire/ -- Most parents get their information about vaccines from their children's doctors, but some also consider public health officials, other parents, friends and family members and even celebrities as sources of vaccine information. These are the results of a national survey conducted by University of Michigan researchers to determine how much parents trust different sources...
-The Company launches the clinical development of its seasonal flu vaccine- QUEBEC CITY, March 21 /PRNewswire-FirstCall/ - Medicago Inc.
BEIJING, March 10, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd.
BEIJING, March 3, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd.
ROCKVILLE, Md., Feb. 28, 2011 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) announced today an agreement to license its proprietary, recombinant virus-like-particle (VLP) vaccine technology to LG Life Sciences, Ltd. (LGLS).
At least one dengue vaccine could be licensed within the next 4 years, as manufacturers are speeding up the development process for multiple dengue vaccine candidates in collaboration with health authorities and developing countries to expedite the necessary testing, clinical trial design, and licensure, a team of leading scientists said.
LYON, France and SWIFTWATER, Pa., Feb. 23, 2011 /PRNewswire/ -- Sanofi Pasteur, the vaccines division of the sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), today will participate in the first international bell-ringing event by a company listed on NYSE Euronext.
ATLANTA, Feb. 23, 2011 /PRNewswire/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX) announced today the publication of the results of Phase 1 clinical trial testing of its HIV/AIDS vaccine products.